Access to Resero’s TurboToxicology™ will provide faster delivery of
high-quality toxicology reports
WILMINGTON, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24CRL&src=ctag" target="_blank"gt;$CRLlt;/agt; lt;a href="https://twitter.com/hashtag/LIFEatCRL?src=hash" target="_blank"gt;#LIFEatCRLlt;/agt;–Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has invested in Resero Analytics™, a software company
focused on providing solutions to the biopharmaceutical industry to
harness its data.
As part of its investment, Charles River will collaborate with Resero
Analytics and is now the exclusive contract research organization (CRO)
partner for TurboToxicology™, a report generation tool that enables
faster delivery of high-quality reports.
TurboToxicology: Fast & Accurate Reports
TurboToxicology analyzes nonclinical data in Standard for Exchange of
Nonclinical Data (SEND) and other structured data formats, and conducts
statistical analyses, applies proprietary algorithms, and displays study
results via visually appealing user interfaces. The tool then
formats the data, in concert with the scientist’s interpretation, to
generate a complete written report that is inclusive of text, tables,
figures, and legends.
TurboToxicology enables the efficient production of consistent formatted
reports, helping to accelerate this step in the drug development process
and thereby accelerating Investigational New Drug (IND) or New Drug
Approval (NDA) submissions.
Leveraging Standardized Data
SEND is an implementation of the Clinical Data Interchange Standards
Consortium (CDISC) Study Data Tabulation Model (SDTM) that provides a
framework for the standardized, electronic representation of individual
research model study data. SEND
is intended to increase the effectiveness and efficiency of data review
for regulatory submissions.
Leveraging structured data, including SEND, allows TurboToxicology to
expedite interpretation and ensure consistency across authors and sites
producing toxicology reports, while enabling sponsor companies to make
quicker decisions by providing robust data early in the reporting
process. This time savings is essential as sponsor companies work to
move potential therapeutics through the drug development pipeline
efficiently, without sacrificing quality.
Approved Quotes
-
“By implementing solutions that increase efficiency in reporting, our
goal is to give our clients the gift of time. By alleviating some of
the upfront administrative work, TurboToxicology’s report generation
tool will allow time for greater focus on other areas of drug
development.” – Birgit Girshick, Corporate Executive Vice President,
Discovery & Safety Assessment, Biologics Testing Solutions, and Avian
Vaccine Services at Charles River -
“With a global network, and the most robust portfolio in preclinical
research, Charles River was the clear CRO partner of choice for
TurboToxicology.” – Dave Watson, PhD, MBA, Founder & CEO at Resero
Analytics
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
About Resero Analytics
Resero Analytics creates data and software solutions for Pharma, CROs,
and Regulators. Our platform improves the quality and timeliness of
toxicology data analysis, interpretation, and reporting. We automate
tasks that are done manually throughout the industry and help clients
make the final call. To learn more, visit reseroanalytics.com.
Contacts
Investor Contact:
Todd Spencer
Corporate Vice
President, Investor Relations
781-222-6455
todd.spencer@crl.com
Media Contact:
Amy Cianciaruso
Corporate Vice
President, Public Relations
781-222-6168
amy.cianciaruso@crl.com